Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm





    Chief Complaint


    Organ System


    Patent Pending

    LEAP trial (2019): Early vs Delayed Levodopa in Parkinson’s Disease


    Leap trial visual abstract parkinson's disease

    LEAP Trial Summary: The LEAP trial was a Multicenter, randomized, double-blind, placebo-controlled, delayed-start trial that randomized 445 patients with Parkinson’s disease (mean age 65) and similar baseline clinical characteristics to early-start group (levodopa + cardbidopa
    for 80 weeks) (n=222) or delayed-start group (Placebo for 40 wks then
    levodopa + cardbidopa for 40 weeks) (n=223). The primary objective of the study was to evaluate whether levodopa has a disease-modifying effect on patients with early Parkinson’s disease who had insufficient disability to warrant treatment with antiparkinson medication. No difference was found in the primary outcome of change in UPDRS score from baseline to week 80 among both groups (p=0.44). The authors of LEAP trial concluded that Treatment with levodopa in combination with carbidopa had no disease- modifying effect, either beneficial or detrimental, on early Parkinson’s disease among patients who were evaluated over the course of 80 weeks.

    Summarized by Ricardo Vivanco

    Source: NEJM